An upcoming US Supreme Court ruling on the legality of the sweeping tariffs that President Donald Trump rolled out in April — briefly sending markets worldwide into a tailspin — could be the next test for stocks that have been flying high.

Cannabis stocks surge. Trump may reclassify marijuana—but White House says a final decision hasn’t been made. Cannabis stocks Tilray Brands and Canopy Growth surged following reports that President Donald Trump would loosen federal restrictions on marijuana. The reaction may be too enthusiastic.

Tilray's premarket rocket — up nearly 30% — wasn't just policy spillover. The company's Amped Live Resin Diamond Sauce vape has quietly become the first major cannabis SKU to generate more incremental revenue than Tilray made selling flower across an entire Canadian province.

The U.S. stock market is having a terrific year. The benchmark S&P 500 ( ^GSPC +0.67%) is up 16% in 2025 despite economic uncertainty created by President Trump's tariffs. But there could be trouble on the horizon.

Shares of Eric Trump’s American Bitcoin Corp. plunged over 50% in minutes as Bitcoin’s month-long selloff deepened.

This article will be updated throughout the day, so check back often for more daily updates. The Vanguard S&P 500 ETF (NYSEMKT: VOO) ended up gaining a modest 0.25% on Thursday, one day after the Federal Reserve cut interest rates by the

During his second term, Trump has imposed broad new import levies that have propelled America’s overall average tariff rate to 18% — the highest since 1934 — while raising costs for U.S. households by $1,600 to $2,600 per year, according to independent estimates.

Trump is expected to tell agencies to reclassify marijuana as a Schedule III drug, The Washington Post reported on Thursday. Such a move would allow cannabis companies to fall under different tax regulations and encourage investment, while placing pot in a class of drug that includes steroids and Tylenol with codeine.